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ABSTRACT

CHARACTERIZATION OF HELICOBACTER PYLORI SRNAS HPNC2525,
HPNC2600, AND HPNC 2645

by
Brandon M. Flatgard
Summer 2020

Helicobacter pylori is a common microaerophilic gram-negative bacterium that
infects approximately 50% of the human population. Although all H. pylori infections
result in inflammation of the gastric epithelium, only 10-15% of infections are
symptomatic and progress to severe gastric diseases such as gastric and duodenal ulcers,
MALT lymphoma and gastric cancer. Different disease outcomes are due in part to
genetic variations among H. pylori strains. Helicobacter pylori strains with a genomic
region called the cytotoxin-associated pathogenicity island (cagPAI) are associated with
an increased risk of severe disease. The cagPAI region encodes a type IV secretion
system that transports the CagA effector into host gastric epithelial cells. Regulation of
the cagPAI is a vital area of research. Previous studies on H. pylori and other bacteria
have found that small RNAs (sRNAs) play a role in gene regulation. These transcripts are
50-300 nucleotides in length and act independently on expressed targets. sRNAs serve to
regulate and fine-tune gene expression by interacting with target mRNA molecules to
inhibit or accelerate gene translation or function. Understanding how cagPAI genes are
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regulated is key to understanding how they promote disease. Herein, I investigate three
cagPAI located sRNAs HPnc2525, HPnc2600, and HPnc2645 identified in previous
studies. Using bioinformatics, conservation, and visual inspection, I predicted promoters
and terminators for HPnc2525, HPnc2600, and HPnc2545. I devised an RT-PCR primer
walking strategy to delimit the 5' end of HPnc2525 further. I analyzed the sRNA
sequences defined by this and previous research using the TargetRNA2 program and
predicted these sRNAs regulate virulence (e.g., cagL, hopZ, and fliA) and other genes.
Due to CoVID-19, I was unable to verify sRNA interactions with their predicted targets
using a plasmid-based GFP expression system.
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PREFACE
Due to the global pandemic of COVID-19, time in the lab was cut short. Instead,
the research took on more a bioinformatic approach to elucidate other aspects of my
research. Much of the preliminary planning and preparation for the physical experiments
were completed, and this will offer researchers taking on the next step a fantastic place to
continue where I left off.

CHAPTER I
Introduction to Helicobacter pylori
Helicobacter pylori is a rod-shaped microaerophilic gram-negative
Epsilonproteobacteria. It is approximately 2.4-4.0 µm by 0.5-1.0 µm and has two to six
flagella that facilitate movement to penetrate gastric mucosa and counteract gastric efflux
mechanisms1. Helicobacter pylori is a human-adapted gastric Helicobacter species
located in the human gastric mucosa of approximately 50 percent of the human
population, making it one of the most common infections in the world1,2. Other
Helicobacter species are zoonotic and rarely can be found on Humans3.
Coevolution between H. pylori and humans share a 58,000-year history with
predominant strains located regionally along with human migration patterns4. The global
distribution of H. pylori genetic diversity is a mirror of its human host, and simulations
have also predicted the spread of H. pylori from east Africa to around the world over the
same time scale of humans4. It has been shown that human populations located in areas
with notably higher documented intestinal parasite load were found to have an immune
response against H. pylori toward a T helper type 2 (Th2) (anti-inflammatory), thereby
preventing T helper type 1 (Th1) responses associated with mediated microbicidal action,
gastric inflammation, and corpus atrophy5,6. This interaction may, in turn, affect the
selection of H. pylori strains in the host, favoring the loss of cagPAI, which is known to
be associated with Th1 type responses5.
Although the H. pylori infection rate is high worldwide, its prevalence varies
dramatically in different regions; prevalence is higher in developing than developed
countries, and in developed countries, infection is inversely correlated with access to
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good sanitation1,2. Regions of Africa and South America were found to have the highest
rates of infection at 70.1% and 69.4% respectively, and Nigeria was found to have the
highest prevalence with 87.7% of the population infected2. In more developed regions
such as North America, the population infection rate is 37.1%2. However, in these
developed countries, it has been found that certain genetic groups have a disproportionate
infection rate compared to the region's average infection rate2. In the United States,
prevalence among non-Hispanic whites ranges from 18.4% to 26.2%. Non-whites
conversely range from 34.5% to 61.6% (Fig. 1)7.

Figure 1. Helicobacter pylori Prevalence Worldwide. (Hooi, J. et al., 2017)
Helicobacter pylori is mainly spread within close family groups who have
diminished access to clean water and are of lower socioeconomic status. However,
infection rates are lower in children and adolescents, although infection tends to occur at
a younger age and is lifelong without antibiotic treatment2,8. The main modes of
transmission are through oral/oral, gastro/oral, and fecal/oral routes1,9. Oral-oral and
gastro-oral transmission occur via direct contact with an infected individual, such as
kissing or sharing unwashed drinking containers10. Helicobacter pylori infection
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prevalence has also been found to be significantly higher among intimate partners via an
oral/oral route10. One is four times as likely to be infected if their partner has H. pylorirelated gastroesophageal reflux. However, the infection can still be spread from
asymptomatic partners but to a lesser extent10. Fecal-oral transmission takes a more
indirect route. Infected individuals can pass H. pylori through fecally contaminated water.
In areas with lower water sanitation standards, H. pylori can be transmitted to a new host
either by drinking contaminated water directly or eating food that has been contaminated
with the unclean water9,11.
Helicobacter pylori Caused Gastric Disease
Although H. pylori infections are common, only 10-15% results in disease12. All
H. pylori infections result in some level of chronic active gastritis, but most do not result
in apparent symptoms or other complications13. Symptomatic infections include gastric
cancer, acute and chronic gastritis, gastric and duodenal ulcers, functional dyspepsia, and
mucosa-associated lymphoid tissue (MALT) lymphoma.
Successful colonization of the host gastric mucosa by H. pylori always results in
acute and chronic gastritis, but these are not always symptomatic13. Acute gastritis is
associated with nonspecific dyspeptic symptoms and also with hyperchlorhydria, the
increased production of acid14. The main dyspeptic symptoms associated with H. pylori
infection are reflux-like with heartburn and regurgitation. Chronic gastritis, because of
permanent colonization, affects acid production and, when coupled with cellular
disruption, can promote different diseases. A combination of H. pylori virulence factors,
host factors, and host environmental factors plays a part in the acid production of the
stomach and, in turn, where it colonizes14. An environment of low acidity leads to more
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broad colonization of the stomach, in the antrum (lower), corpus (middle), and fundus
(upper), which is associated with gastric carcinoma15. Conversely, an environment with
higher acid production leads to more limited stomach colonization, mainly in the gastric
antrum, which has a lower number of acid-secretory cells. This antral-predominant
gastritis from H. pylori colonization is the leading cause of peptic ulcer disease (PUD)
(Fig. 2)14.

Figure 2. Locations of Helicobacter pylori Colonization
With a combination of host and environmental factors, H. pylori can colonize distinct
locations in the stomach leading to different disease states. Pink areas represent increased
acid production and colonization.
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Helicobacter pylori was discovered in 1983 to be a cause of PUD and is still
regarded as the primary pathogen associated with it2,3,16. PUD is caused by defects in the
gastric mucosa that occur along with the transition from the corpus to antrum17.
Helicobacter pylori presence has been found in about 82% of duodenal ulcers and 68% of
gastric ulcers18. The risk of PUD is 3 to 10 times greater in people with H. pylori
infection than without19. Eradication of the infection by antibiotic treatment or triple
therapy (oral proton pump inhibitor, clarithromycin, and amoxicillin) has been found to
reduce the risk of this disease20.
Chronic infection with H. pylori is linked to gastric adenocarcinoma and MALT
lymphoma, which accounts for 25% of cancers associated with infectious agents21.
MALT lymphoma was first associated with H. pylori in 1991 and is now known to be
responsible for 92-98% of all gastric MALT lymphoma21. This type of lymphoma is a
non-Hodgkin B-cell neoplasm, which originates from the marginal zone of lymphoid
follicles22. Although not contributing to increased risk, the presence of the H. pylori
virulence protein cytotoxin-associated gene A (CagA) in tumor-associated B cells
correlated with earlier pathogenic remission times, possibly due to the translocation of
CagA into malignant B cells23. Eradication of H. pylori leads to remission in 80% of
MALT lymphoma patients, but other cancers have been linked to H. pylori infection,
such as Pseudomyxoma peritonei (PMP), laryngeal/pharyngeal cancer, and other
lymphomas12,24. Pre-surgery H. pylori eradication with these other cancers has shown an
increased length of patient survival over non-treated patients12,24. Helicobacter pylori is
currently identified as a Group I carcinogen by the International Agency for Research on
Cancer25.
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Functional Dyspepsia, or non-ulcer Dyspepsia, is one of the most common
sensorimotor disorders involving the gastrointestinal tract26. It is defined as the presence
of one or more of the following symptoms: bothersome postprandial fullness (full
stomach feeling), bothersome early satiation (inability to eat), bothersome epigastric pain
(upper abdomen), or bothersome epigastric burning (heartburn), and no evidence of
structural disease (including upper endoscopic findings) to explain the symptoms27. The
main symptoms of H. pylori are reflux-like with heartburn and regurgitation. It may be
similar to ulcer-related dyspepsia, causing pain and vomiting. Of patients that exhibit the
symptoms associated with Functional Dyspepsia, it is estimated that 30-60% carry H.
pylori28.
Our initial understanding of the role of H. pylori-induced carcinoma was believed
to be the result of a long-term inflammation process. Whereby a Th1 type immune
response led to the apoptosis of gastric epithelial cells and thus increased cell growth to
compensate29,30. This damage led to errors during mitosis and accumulated mutations in
the host cells, which is further compounded by a deficiency of the DNA mismatch repair
mechanism in the host cells induced by H. pylori infection31. Recent studies have
suggested that the CagA protein may also have a carcinogenic effect via interactions with
proteins of the tight junctions and adherent junctions, leading to a breakdown of these
junctions and uncontrolled activation of β-catenin, which will lead to tumor
production3,32,33. Conclusive evidence for this interaction and carcinogen nature was
shown in transgenic mouse experiments34.
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Helicobacter pylori Caused Extragastric Disease
Extragastric diseases with which H. pylori infection may also be associated
include iron deficiency anemia, idiopathic thrombocytopenic purpura (ITP), skin
diseases, pregnancy diseases, liver and gallbladder, pulmonary, ocular,
neurodegenerative, cardiovascular, autoimmune, neuromyelitis optica, multiple sclerosis,
insulin resistance, diabetes, and ear nose and throat12. Helicobacter pylori's presence in
these different areas of the body shows that it is not just isolated to the stomach, as was
initially thought. Other than the stomach, H. pylori has been cultured and observed
histologically in the nasal cavity, coronary arteries, liver, and peritoneum12. The
relationships and their significance of H. pylori in these extragastric locations are debated
and are still being investigated.
Factors Affecting Disease Outcome
Human factors affecting disease outcomes include age, alcohol intake, nicotine
intake, and salt intake7. These factors all affect H. pylori antibody serum levels but in
separate ways. For example, age, salt, and nicotine intake are associated with a marked
increase in serum antibody presence35-37. Nicotine causes vasoconstriction body-wide,
thus reducing mucosal blood flow, epidermal growth factor secretion, and mucus
secretion36. High salt concentration in the stomach was found to alter the H. pylori
exoproteome, increasing the secretion of the H. pylori virulence factor VacA35. Alcohol,
however, has an inverse effect on antibody serum levels, which is believed to be the
result of lower pH in the stomach due to increased stimulation of gastric acid secretion38.
Human genetic diversity can also lead to differing immune responses, which in
turn can affect disease states. Increased gastric cancer risk can stem from functional

9

polymorphisms in the genes encoding interleukins (ILs). ILs are a group of cytokines,
proteins, and other signaling molecules, which are an essential part of the immune
system. In particular, functional polymorphism in IL-1β (responsible for antimicrobial
resistance and inflammation) and IL-1 receptor antagonists (the natural inhibitor of the
proinflammatory effects of IL-1β), as well as differing the amount of IL-1β secreted from
the microbial response, have shown to increase gastric cancer risk39. An increase in
colony density in patients lacking blood group antigen Leb has been noted as well40.
These individuals are lacking Leb due to the fact they genetically have no Le gene or they
have an Le gene but no Se gene41. Other polymorphisms exist in genes, increasing
proinflammatory cytokines or reducing anti-inflammatory cytokines. Helicobacter pylori
primarily mediates a Th1 response42. This response is associated with proinflammatory
cytokine release, such as the cytokine important for innate and adaptive immunity against
viral, some bacterial and protozoal infections, interferon-gamma (IFN-γ), as well as the
activation of macrophages. This strong Th1 response leads to worse outcomes due to
chronic inflammation and gastric atrophy. However, a Th2 response can mediate this
effect43. There is a noted Th1 bias in patients from Japan and the United Kingdom who
also present a higher level of disease44.
Conversely, human populations in Africa present a lower instance of disease
levels with a marked increase of Th2 response instead of Th144. The mechanism for
controlling Th response in humans is comprised of regulatory T-cells (Tregs), which are a
specific population of T-cells that can maintain homeostasis and self-tolerance by
suppression of the immune response45. The gastric mucosa of H. pylori-positive
individuals contains high levels of immunosuppressive cytokines IL-10 (anti-
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inflammatory) and transforming growth factor beta 1 (TGF- β1), which controls
proliferation and differentiation of many cell types46. Tregs also suppress IL-8 (induces
chemotaxis and stimulates phagocytosis) production from gastric epithelial and memory
cell responses in the presence of H. pylori46. Helicobacter pylori can induce a Treg
response, which may be a reason for its relatively benign coexistence with the human
host. However, patients with PUD have decreased Tregs in their gastric mucosa, which
highlights the importance of a balanced regulatory response47. Coevolution between H.
pylori and humans spans 58,000-years, and while the human genetic diversity plays a role
in disease, so does the genetic diversity of H. pylori itself4.
Bacteria Genetic Diversity Promoting Disease
There are four steps crucial for H. pylori colony establishment and pathogenicity,
and the presence of genes required for these steps varies among H. pylori strains. When
entering the host stomach, H. pylori must be able to survive in the acidic stomach.
Survival is facilitated by the production of urease, which hydrolyzes host produced urea
to ammonia and carbonic acid, serving as a buffer to the microenvironment enabling
colonization (Fig. 3).
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Figure 3. Helicobacter pylori can Neutralize Stomach pH
To successfully colonize the gastric mucosa, H. pylori neutralizes urea with urease. The
pink area represents a high acid environment (≤ pH 2), and the blue area represents a
lower acidity environment (≥pH4) due to the effects of urease. Urea from the
environment enters through proton-gated channels (orange) on the surface of the
bacterium. Urease breaks down the urea creating CO2 (orange square) and NH3 (blue
triangles). The latter is excreted through proton-gate channels on the surface of the
bacterium, raising the pH in the vicinity.
The urease gene cluster contains seven genes, including catalytic subunits (ureA/B), an
acid-gated urea channel (ureI), and accessory assembly proteins (ureE-H)48. To prevent
lethal alkalization, this activity is regulated by the proton-gated urea channel UreI. This
regulation functions by only being active under acidic conditions, such that UreI channels
in the inner membrane are closed at pH 7.0 and fully open at pH 5.049. The surface of H.
pylori also contains urease, which allows the bacteria to pass through the gastric
environment unscathed49. Furthermore, urease has been found to regulate macrophage
interactions by modulating phagosome pH and megasome formation and reduce the
viscosity of gastric mucin50,51.
While traversing the gastric mucosa, the next crucial step in colony establishment
is the ability to move further toward epithelium cells. Helicobacter pylori, motility is
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directly correlated with a rise in pH. Helicobacter pylori achieves motility by reducing
the viscosity of its environment; it does not bore its way through the mucus gel, as
previously thought50. It can then move through the gastric mucosa epithelium layer
toward the basal layer when the pH is more neutral, and the bacteria have disrupted the
tight cell junctions. Both its helical shape and flagella help it move into its
microenvironment. Helicobacter pylori rotates as it swims, producing a helical trajectory,
but the relatively slow body rotation rates make only a 15% contribution to propulsive
thrust52. Thus, the flagella have more of an impact on motility than its helical shape. This
flagella-mediated motility is one of the most complex systems in H. pylori, with more
than 40 proteins involved in biosynthesis and operation53. More severe pathological
outcomes have been observed in patients infected with H. pylori strains with higher
motility54. There is still debate about whether flagella directly participate in cell adhesion.
However, it was found that regulators controlling flagella genes may affect adhesin
expression as well55.
Neutrophil-activating protein A (napA), a gene encoding H. pylori-NAP (HPNAP), is highly associated with chronic gastritis, as well as infiltration of neutrophils and
mononuclear cells into the gastric mucosa56. HP-NAP is a member of the DNA-binding
proteins from starved cells (Dps) family, which is highly similar to other bacterioferritin
that store iron and bind and protect DNA57. However, HP-NAP differs as it induces large
quantities of IL-12 and IL-8 via stimulation of both neutrophils and monocytes58,59. This
stimulation, in turn, induces T-cells to secrete INF-γ and mediates the shift to a Th1
response58. This adhesion to neutrophils causes damage to local tissue by stimulating a
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high production of oxygen radicals60. HP-NAP also facilitates another adhesin, SabA, by
mediating the binding of sialylated antigens on the host cell surface61.
Both variably expressed blood group antigen-binding adhesin (BabA) and sialic
acid-binding adhesin (SabA) facilitate colonization of the epithelial layer of the antrum of
the stomach3,12. BabA binds to fucosylated Lewis B blood-group antigen that is expressed
on the gastric epithelium cells62. Interestingly, strains that are deficient in BabA resulting
from mutation still express a chimeric BabB/A, which can bind to the Leb antigen by
genetic recombination in certain conditions63,64. SabA, on the other hand, recognizes the
sialyl-Lewis A antigens sLex and sLea 65,66. Thus, the interaction of SabA and sLex
antigen enhances H. pylori colonization in patients with weak or no Leb expression.
After the pH has been addressed by urease and adhesion of H. pylori to epithelial
cells occurs, the bacterium secretes or injects additional virulence factors into the
cytoplasm to impact host cell physiology such as muramyl dipeptide (MDP) and
Vacuolating toxin A (VacA) into their cytoplasm67. MDP, which is part of the
peptidoglycan cell wall, is detected by the intracellular NOD receptors. These, in turn,
activate the Nuclear factor-κB (NF-κB) pathway with the production of IL-8 and attract
inflammatory cells67. Ultimately this immune response was found to be one-way
epithelial cells that can differentiate pathogenic and non-pathogenic bacteria67,68. The
presence ImaA, immunomodulatory autotransporter protein, can decrease this
inflammation responses aiding in overall pathogenesis of H. pylori69. Also, VacA may
induce many large vacuoles in host cells (Fig. 4).
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Figure 4. Virulence Factor Vacuolating Toxin A (VacA)
VacA enables H. pylori to remove nutrients from host cells when bound to the epithelium
by an autotransporter system. VacA also promotes proinflammatory signaling,
vacuolation (membranous spaces in the host cell cytoplasm), apoptosis, and after tight
cell junction disruption, disruption of T-cell activation and proliferation.
There are multiple alleles of vacA with different activities and different levels of
expression that impact disease outcome70. VacA forms an autotransporter structure to
secrete itself from H. pylori without the need for host cell contact12. VacA has been
shown to disrupt the barrier function of epithelial cells, allowing leakage of essential
nutrients needed by H. pylori for growth71. VacA embeds into the host cell membrane
and functions as an anion-selection channel releasing bicarbonate and organic anions in
the host cytoplasm72. In addition to embedding, VacA can also be endocytosed and allow
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anions to enter late endosomes, creating large vacuoles71,73. Acute inflammatory
responses can also be achieved by inducing the host cell to release IL-874. VacA also can
cause mitochondrial dysfunction resulting in apoptotic death of the cell and T-cell
blocking71. The presence of VacA can have a dramatic effect on epithelial cells; however,
it is not clear whether VacA primarily causes a disease. Thus, it is believed that the
ability of H. pylori to colonize a host successfully is merely enhanced via VacA75.
The most significant and well researched H. pylori virulence factor is CagA. It
will not function in isolation and works in concert with other virulence genes, those in the
cagPAI genomic region12. This island is present in about half of the H. pylori strains, and
its presence correlates with more severe disease states3,67,76. The cagPAI genes encode a
type IV secretion system that enables the injection of CagA into host cells71. Once in the
host cell cytoplasm, CagA is phosphorylated, which inhibits Src dephosphorylation,
regulation of cellular matrix, and other cytoskeleton regulators in epithelial cells68,77.
These will phenotypically change the cell and cause high markers of gastric cancer stem
cells, the so-called hummingbird phenotype (Fig. 5)3,71,78.
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Figure 5. The Type IV Secretion System Injects CagA into the Epithelial Cell
CagA disrupts the tight cell junction and disrupts the cellular matrix resulting in a
hummingbird morphology. NOD1 also gets activated by iE-DAP, which in turn activates
NF-κB, which subsequently produces proinflammatory signaling.
Africa has been shown to have the highest prevalence of infection, even though the
reported cases of gastric cancer were lower than regions with lower infection
prevalence2,79. The most prevalent strain of H. pylori in South Africa, shpAfrica2, was
found to lack the cagA gene2. Further studies have shown that increased pathogenicity
correlated with the more virulent strains to create morphological changes, vacuole
formation, and progressive epithelial cell degeneration13. There is a noted positive
correlation with the severity of disease, and cagA-positive H. pylori strains in both
humans and animals13,80.
Not all virulence factors are present in each strain of H. pylori. Although, all
known H. pylori strains contain vacA genes, not all the strains produce a functional VacA
protein due to genetic polymorphisms81. BabA is almost always present in CagA positive
strains, and the presence of cagA usually correlates with the presence of vacA, and
proinflammatory outer membrane protein (oipA)12,56,82. The pathogenicity of H. pylori is
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a result of several genes that are responsible for the production of these virulence factors,
each playing their part.
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CHAPTER II
Small Regulatory RNAs
Regulatory RNAs (riboregulation) have been linked to bacteria pathogenicity83.
Helicobacter pylori was previously believed to lack riboregulation, but recent studies
revealing sRNA activity in H. pylori have challenged previous conclusions84,85. RNA
regulators in bacteria are transcripts that use various mechanisms to change expression
and promote a range of physiological responses86. These regulators come in different
classes, such as riboswitches, small transcript binding proteins, CRISPR RNAs, and
sRNAs86. The sRNA molecules are post-transcriptional regulators found in all kingdoms
of life. They are short transcripts roughly 50-300 nucleotides in length and act on
expressed mRNA targets through complementary base-pairing87. These interactions serve
to regulate and fine-tune gene expression by inhibiting or accelerating mRNA translation
through impacting access to the ribosome binding site and by impacting mRNA
stability86. Of the various sets of sRNA, the most extensively studied are regulators that
act through base pairing with mRNAs to affect their translation86. Cis-encoded antisense
sRNAs are located in or near the same gene locus as their mRNA target and share
complete base-pairing with their target, usually within the untranslated 5' region (Fig.
6a)88. Alternatively, trans-encoded sRNA, whose target is genetically distant loci, has
only partial and interrupted base pairing with its target (Fig. 6b)88. The last known
interaction is Cis-encoded antisense acting in trans, which involves two sRNA
interactions, one in cis and one or more in trans (Fig. 6c)88.
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Figure 6. sRNA Can Post-transcriptionally Regulate Genes in Diverse Ways
(A) Cis-encoded antisense sRNA with complete base pairing with mRNA can form a
complex of the coding region that gets degraded. (B) Genetically distant trans-encoded
sRNA has only partial and interrupted base pairing that can enable upregulation by
binding with the mRNA and opens access to the ribosome binding site. (C) Cis-encoded
antisense acting in trans sRNAs involves two interactions, one in cis and one in trans.
The sRNA can downregulate expression by binding to the ribosome binding site, thus
blocking translation
The majority of known sRNAs act by the cis-encoded antisense acting in trans
mechanism whereby the cis-encoded sRNA acts both on the mRNA target it overlaps and
mRNA targets at genetically distant loci86,88. The sRNAs can globally affect traits
resulting from stress responses, adaptive metabolic changes, virulence, stalled ribosomes,
uncharged tRNAs, elevated temperatures, or small molecule ligands at the posttranscriptional level89. Hence, sRNAs have evolved as an additional form of gene
regulation90.
In some instances, proteins aid the sRNA to facilitate regulation. Helper proteins
like Hfq often play critical roles in sRNA function. However, Epsilonproteobacteria,
including H. pylori, have no apparent Hfq homolog91,92. Hfq is an RNA-binding protein
that forms homohexamers of ~12 kDa subunits, which protects the sRNA to prevent
degradation and allow the sRNA to bind to its mRNA target92. Although all forms of life
contain sRNA, not all of them are the same, and it is not currently known how sRNAs
work in H. pylori given the apparent lack of helper proteins.
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Different methods, such as computer-aided target prediction and functional
assays, have been developed to find the sRNAs targets. A biocomputational method
(TargetRNA) was developed to predict targets of sRNAs using a calculated hybridization
score for a given sRNA and a candidate mRNA candidate93. This tool was later refined to
update efficiency and accuracy and is freely accessible on the web as TargetRNA293,94.
Reporter assays have been developed to analyze sRNA-directed gene control that can be
used for co-expression of an sRNA and a 5' sequence of an mRNA target fused to a green
fluorescent protein (GFP) reporter95. Using this method, expression of the mRNA
directed by the sRNA can be visualized by cloning GFP plasmids96. A super folder
variant GFP (sfGFP) was later created, which results in increased ﬂuorescence of target
fusions, which is beneficial when the proteins do not fold flawlessly but still affect
expression97.
Role of Helicobacter pylori sRNA
The H. pylori genome encodes relatively few transcriptional regulators, so how
does it regulate all of its gene expression to respond to changing environmental
conditions98. A potential answer came with the publication of four studies that together
identified in excess of 60 H. pylori sRNAs. Livney et al. (2006) used sRNAPredict2 to
identify sRNAs in intergenic regions with regards to the conservation of transcriptional
regulatory elements, Rho-independent terminators, promoters, and with a size constraint
of 60-550 nt in length99. They identified a total of 130 among six different strains of H.
pylori; 50 were unique, 49 were conserved in at least two strains, and 29 were at least
conserved in 3 strains99. Xiao et al. (2009) predicted six sRNAs based on gene location,
promoter search, and terminator search100,101. Intergenic regions were screened in H.
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pylori strain 26695 using pftools 2.2 to identify promoters, RNAmotif to identify hairpins
followed by UU nucleotide sequences, and finally, if a promoter and terminator pair on
one strand between 45 and 350nt between them100,101. These potential sRNAs were
analyzed for conservation, which identified six sRNAs, and two were experimentally
confirmed by Northern blot and RT-PCR100,101. Even though many sRNAs have been
identified, only four have been well characterized. For example, a novel cis-encoded
antisense small RNA was identified, which downregulated expression of the urease
component, UreB, at neutral pH85. It was found that 5'ureB-sRNA, targets the 5' end of
ureB and promotes premature termination of transcription of ureAB mRNA85. With this
mechanism, a limited amount of 5'ureB-sRNA is sufficient to regulate the relatively high
level of ureAB transcript102. This process effectively prevents urease from being produced
when the environment does not demand it (Fig. 8a).
The second characterized sRNA, a trans-encoded sRNA repG, was shown to
target a homopolymeric G-repeat in the mRNA leader of an acid-sensing chemotaxis
receptor, TlpB84. This regulation of tlpB, which decreases expression could be necessary
for H. pylori colonization, and research is still ongoing (Fig. 8b)84. Another H. pylori
sRNA, CncR1, which is located in the cagPAI, has also been characterized76. CncR1 was
found to target flagellar functions, specifically the flagellar checkpoint gene fliK. This
downregulation, in turn, affects motility and adhesion (Fig. 8c)76.
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Figure 7. Different regulation of Helicobacter pylori sRNAs.
(A) Urease expression changes based on the acidic environment. 5'ureB-sRNA, a cisencoded antisense small RNA downregulates expression of the urease component, UreB,
at neutral pH. (B) sRNA repG targets a homopolymeric G-repeat in the mRNA leader of
an acid-sensing chemotaxis receptor, TlpB. This regulation of tlpB decreases the
expression of quorum and acid-sensing. (C) sRNA CncR1 targets the flagellar checkpoint
gene fliK when adhered to epithelial cells. This downregulation, in turn, negatively
affects motility.
The most recent sRNA characterized is HPnc4160, discovered by Sharma et al. (2010),
was recently found to regulate cagA, which was confirmed by comparing RNA-seq and
iTRAQ analysis between wild-type and HPnc4160 deficient mutant strains103. HPnc4160
is expressed lower in patients that develop gastric cancer, showing that in the absence of
HPnc4160, CagA can be expressed more readily, increasing virulence103.
Characterizing H. pylori cagPAI sRNAs
I am interested in sRNAs because of their intricate relationship with gene
regulation. I want to learn about them in general and how they contribute to the
regulation of gene expression and specifically virulence gene expression. Two previous
studies (Sharma et al., 2010 and Ta et al., 2012) identified sRNAs in the clinically
relevant cagPAI. I focused on analyzing two sRNAs, HPnc2620 (Sharma et al., 2010)
and HPnc2525 (Ta et al., 2012), from this region in hopes of finding sRNAs with cis-
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regulation of cagPAI genes. I chose to analyze one sRNA, HPnc2660, whose full length
was identified by Sharma et al. (2010) and a second sRNA, HPnc2525, for which a
partial transcript was identified by Ta et al. (2012) and Baber and Castillo unpublished).
Focusing on the cagPAI region, one sRNA was selected from the database generated by
Sharma et al. (2010) to be characterized, HPnc2600.
Additionally, three more cagPAI sRNAs that were identified by their promoter
regions by Ta et al. (2012) were selected. These promoters were not located upstream of
known cagPAI genes but rather were positioned to direct expression opposite and to
overlap known cagPAI genes cagE, cagY, and cagN, suggesting that these regions may
encode sRNAs104. Reverse transcription-PCR determined that these promoters did, in
fact, direct expression of a transcript and these transcripts104. Preliminary work by C.
Baber and A. Castillo cloned regions of HPnc2525, and HPnc2645 but did not identify
the entire sRNAs (Table 1). My goal was to analyze and characterize sRNAs HPnc2525
and HPnc2645 from Ta et al. (2012) as well as HPnc2600 discovered by Sharma et al.
(2010).
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Table 1. sRNA Sequences (C. Baber and A. Castillo.)
Sequence discovered by TaKaRa SMARTer 3'/5'RACE highlighted in yellow. Extended
sequence discovered by walking primers highlighted in green.
mG27 Genomic
sRNA
Sequence (5' end)
Position
HPnc2525 TATACCTGTGCTACTTTAGAAGTCAGAGT
521426-521677
GATTTCAATAGGGGTGTATTGCGCTAAAA (antisense to cagY)
CAAATGTGGGATCACTCTTGCCTATAAAG
GCCTGTTTGACAGGGCTTGTTTCATCTTGT
TTTTCTTCTTTCTTTTTATCGTCAATGGGA
TTACCATTTTCATCTACAAAATCCCCACT
CTTTTCTTTTTTGTTCTTAAGAGCGATTTC
ACTGATATTCTTAGCAGTTTCTGCGACAT
CTTTGT
HPnc2645 CTCTAGTTGTTTTTTGATCTAATAATTTTG
539120-539199
ATCGCTATTTTTTCCATGAGCGATGCTTTG (sense to cagU)
TTCTATTTGATTAATGACG
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CHAPTER III
Methods
Bacterial media and culture condition
Helicobacter pylori G27 was grown on Columbia blood agar plates (Appendix)
using the CampyGen 2.5L Atmosphere Generation System and incubated at 37oC.
Escherichia coli media consisted of LB Broth and Agar grown incubated at 37oC
overnight. Plasmids were selected by addition of the appropriate antibiotics, ampicillin
(100ug/ml), chloramphenicol (20ug/ml) to liquid and solid media.
RNA isolation
Helicobacter pylori strain G27 was cultured as above for three days, then passed
for two days and then a third time for one day to generate a large number of cells in the
log phase of growth. Bacterial growth from ½ plate was collected and resuspended in
300µl Trizol and mixed thoroughly. Samples were stored at -20oC until used for
extraction. For extraction, a Zymo RNA Mini-prep Plus kit was utilized per instructions
(Zymo). Two H. pylori + Trizol tubes were used per extraction, each added to the column
after being spun. DNaseI was added during extraction, then eluted with 50µl
RNase/DNase free water. The RNA concentration and purity were measured using
NanoDrop. Additional DNase treatment was required to remove all contaminating
genomic DNA from the RNA samples following the ThermoFischer protocol for DNaseI.
The DNase treated RNA was ran through the RNA Mini-prep plus procedure again to
remove the enzymatic activity. RNA was stored at -80oC.

26

Strains used for the study
Helicobacter pylori G27was used for this study for analysis and culture.
Escherichia coli strains DH5-a and MC1061 were used for propagating plasmids and the
plasmid assay (Future Directions).
Reverse transcription-PCR to Determining 5' and 3' ends of sRNAs
RT-PCR was completed in two steps using SuperScript IV One-Step RT-PCR
with ezDNase in 10µl reactions with modifications as follows from the manufacturer's
protocol (ThermoFisher). Two steps were used to prevent transcription of cagY due to the
intergenic location of HPnc2525. The first step (reverse transcription) included all
reagents except for the forward primer. The forward primer was added for the second
step, starting DNA amplification.
Oligonucleotides
The sequences and names of all oligonucleotides used for reverse transcription,
PCR, and cloning in this study are included in table 2.
Table 2. Oligonucleotides Used in this Study
Name
Sequence (5' end)
PIX-F
CACTCTTGCCTATAAAGGCC
PIX-F2
AATGTGGGATCACTCTTGCC
PIX-F4
GGGTGTATTGCGCTAAAACA
PIX-F8
TATACCTGTGCTACTTTAGA
PIX-R
GAAACTGCTAAGAATATCAGTG
PIX-Rnew
TATCAGTGAAATCGCTCTTAAGAACA
PIX-R2
AGATGTCGCAGAAACTGCTA
PIX-R4
GAAAGCAATCCGATGACAA
PIX-R9
GTGGCAATAAAAAAGATGACGATAAAG
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Promoter Prediction
Transcriptional promoter and terminator sequences define the DNA region
transcribed to RNA. Here I analyzed DNA regions around and within HPnc2525 and
HPnc2645 for promoter and terminator consensus sequences to define better the entire
transcripts (identified in this study and by Ta et al., 2012). I also analyzed HPnc2600, an
sRNA identified by Sharma et al. (2010) for which the entire transcript is known, but for
which the promoter and terminator sequences have not been identified, to test my
identification methods.
To transcribe their genes, prokaryotic species only have a single RNA
polymerase. However, they can have multiple sigma factors making up a part of the RNA
polymerase complex that directs binding to the promoter105,106. H. pylori has three known
sigma factors, fliA (Ϭ28), RpoN (Ϭ54), and RpoD (Ϭ70)107. These sigma factors have a
preference to bind distinct sets of promoters containing two short sequence elements,
usually around 10 (called -10) and 35 (called -35) nucleotides upstream from the
transcription start site (TSS, also called +1)105. There is no single consensus for these
sequence elements in H. pylori, and, to elucidate what these elements may be, an in-depth
sequence analysis with many H. pylori strains needed to be employed. For HPnc2600, the
transcription start site (TSS) was identified (Sharma et al., 2010) and so I analyzed the
50bps upstream of the TSS for sequences that matched or were similar to known H.
pylori promoter sequences (Table3)107. In addition to this, I used another program that
predicts binding of this same region with Virtual Footprint108. This program looks for
promoter motifs for -10 and -35 sites of different bacterial species. My search only
included promoters for fliA (Ϭ28), RpoN (Ϭ54), and RpoD (Ϭ70) in Escherichia coli.
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Table 3. Previously Discovered Promoter -10 Sequences
There is no clear consensus for -35 in H. pylori. Studies, where a -35 found, are listed.
Studies where no -35 or drastically differing -35 sites and noted with a dash.
Reg
-35
-10
Source
Ϭ70
TAAAAG Forsyth & Cover, 1999 109
AATAAT Odenbreit, Wieland, & Haas, 1996 110
TAAAAT Spohn & Scarlato, 1999 111
TATTAT Beier et al., 1998 112
TACAAT Shirai et al., 1999 113
TATAAT Spohn & Scarlato, 1999 111
TATAGT Suerbaum,1997 114
TAACA
Jones et al., 1997 115
AATAG
Spohn & Scarlato, 1999 111
TTCGGT Ge & Taylor, 1996 116
CTTCTT Heuermann & Haas, 1995 117
TACAAT Pesci & Pickett, 1994 118
CGAGTG TGATAA Spohn et al., 1997 119
TAGTTT GCACTA McGowan et al., 2003 120
GCGCGA GCTAGC McGowan et al., 2003 120
GTCAAA TCTAAA McGowan et al., 2003 120
TAGAAT McGowan et al., 2003 120
TAATTT TGGAAT McGowan et al., 2003 120
ATTAAG TATAAA McGowan et al., 2003 120
TAAGGT GAAAAT McGowan et al., 2003 120
TTCAGC TTTAAT McGowan et al., 2003 120
ATGCAT TAAATT McGowan et al., 2003 120
TTTGCTT Niehus et al., 2004121
Ϭ54 TTGGTA
TGCAA
Josenhans et al., 2002 122
TTAGAA
TCGCA
Josenhans et al., 2002 122
Ϭ28
TaAA
cCGAT
Spohn & Scarlato, 1999 123
Josenhans et al., 2002 122
Another method I used to predict the sRNA promoter sequence was overall
conservation among currently completely sequenced H. pylori strains was BLAST124. I
reasoned that nucleotides that are part of a functional sequence would exhibit more
conservation that those that were not111. I conducted a microbe BLAST consisting of 50nt
upstream of the sRNA gene that was used to determine the conservation of the predicted
promoter sequence124. These results were analyzed further using the multiple alignment
tool, MAFFT (multiple alignment using fast Fourier transform) v7.464, with auto-
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algorithm125. For HPnc2525 and HPnc2645, I believed the TSS of HPnc2525 and
HPnc2645 might extend beyond the experimentally determined 5' ends. I analyzed
sequences from the experimentally determined 5' end to the 5' end of their functionally
identified promoters.
Terminator Prediction
Two types of bacterial transcriptional terminators control gene termination, Rhoindependent (RIT) and Rho-dependent (RDT), either of which is located downstream
from the codon, typically within approximately 50 nt of the 3' end of the transcript126-128.
RIT destabilize and dissociate the elongating transcription complex of the transcript
relying solely on interactions of DNA and RNA with RNA polymerase by an intrinsic
secondary hairpin structure with minimum free energy (ΔG) <-3.0 kcal/mol, a loop size
of 3-10 nt, a stem is between 4-15 nt and a thymine-rich region should be within 20 nt of
the hairpin structure126,129. Rho-dependent terminators use an RNA helicase, Rho, to help
dissociate at specific sites on the transcript39. I used RhoTermPredict to find sequences
RDT; this program searchers for RDT consensus sequences (Rho utilization site, RUT),
a motif comprising of a 78 nt with regularly spaced C residues, higher C than G content,
as well as a putative pause site for RNA polymerase (hairpin structures)130. I searched
both RDT and RIT sites since H. pylori can contain either126.
This method failed to predict any Rho-dependent terminators for HPnc2600 and
HPnc2645., which may indicate a lack of Rho-dependent termination; thus, both were
analyzed for intrinsic terminators. The criteria for intrinsic terminators outlined by
Castillo et al. (2008) include a stem of 4–18bp, a stem of 9–18bp with a loop comprising

30

<20% of the stem length, or stem of 7–18bp with a 1 to 5 nucleotide bulge in either the 5′
or 3′ side of the stem126.
sRNA Target Prediction
The sRNA target prediction program TargetRNA2 was used to analyze
HPnc2600, HPnc2525, and HPnc2645 to identify candidate genes that may be regulated.
The sequences used for prediction only included what was experimentally identified, not
the sequences predicted with the in-silico analysis for the promoter and terminator
extensions. Predicted targets were obtained using TargetRNA2 with default p-values <
0.010 94. This software developed the secondary structure of the sRNA, the secondary
structure of each candidate mRNA target, and the hybridization energy between the
sRNA and each candidate mRNA target to determine potential targets94. Accurately
predicted targets had a match of ≤0.005. were considered putative targets, except cagPAI
targets or other interesting targets in HPnc2600. Unlike HPnc2525 and HPnc2645, the 5'
and 3' ends are known. Meaning the full transcript of HPnc2600 has been identified, as
discovered by Sharma et al. (2010). However, like HPnc2525 and HPnc2645, HPnc2600
is located in the clinically relevant cagPAI region. This location indicated that Hpnc2600
might regulate the expression of cagPAI genes due to the conservation of both the sRNA
and cagPAI genes in multiple strains.

31

Results
Experiments conducted by Ta et al. (2012) functionally identified promoters that
regulate HPnc2525 and HPnc2645 and also an expressed transcript representing
HPnc2645 104. Subsequently, TaKaRa SMARTer 5'RACE was used to tentatively
identify the 5' and 3' ends of sRNAs HPnc2525 (202bp, located at 521475-521677) and
HPnc2645 (79bp, located at 539120-539199, Castillo and Baber, unpublished results,
Table 2, Fig 8).

Figure 8. Subsection of cagPAI
Genes are represented by thick black arrows oriented in the direction of transcription.
Promoters are represented by thin black flags pointing in the direction of transcription.
Red arrows represent sRNA genes pointing in the direction of transcription. The lengths
and spacing are approximately proportional.
Because the 5' end of HPnc2525 and HPnc2645 did not extend into the sequence that
defines the functional promoters (PHPnc2525, 521375-521506; PHPnc2645, 539314539259, Ta et al., 2012), we believe the TaKaRa SMARTer 5'RACE defined transcripts
may be incomplete; this could result from the use of an RNA template that was degraded.
To determine if the 5' and 3' ends of HPnc2525 extends beyond what was
identified by TaKaRa SMARTer 5' RACE, I isolated RNA from H. pylori strain G27 and
used it as the template for an RT-PCR walking strategy. I used agarose gel
electrophoresis to verify that the RNA was not degraded and would represent full-length
transcripts free of impurities such as chromosomal DNA, proteins, and endotoxins. RNA
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concentrations were between 98ng/µl and 133.6ng/µl, and A260/A280 readings were
between 1.73 and 1.94. (Fig. 9).
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Figure 9. RNA Samples Used for RT-PCR Experiments
The RNA was not degraded. 5ug of the RNA samples were resolved on a 2% agarose gel.
The 16S and 23S ribosomal RNA bands are visible in the intact RNA sample.
Oligonucleotides for the walking RT-PCR were designed with ten bp overlap
upstream and downstream of those used to generate TaKaRa SMARTer 5'/3’ RACE
products.
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The upstream walk was conducted using PIX-Rnew for reverse transcription and
then paired with PIX-F, PIX-F4, PIX-F6, or PIX-F8 in separate PCR reactions. A
transcript was detected in each of these PCR reactions indicating that the sRNA was
being transcribed. The 5' end of HPnc2525 extends at least to the 5' end of PIX-F8
(521426). This result puts the 5' end of HPnc2525 upstream of the 5' end of the cloned
functional promoter. For the downstream walk, oligo PIX-Rnew, PIX-R, or PIX-R2 were
used to conduct the reverse transcription step and then paired with PIX-F for PCR. This
result indicates that the HPnc2525 3' end extends to at least the 3' end of oligo PIX-R2
(521643-521662) and the 5'end of PIX-F8 (521426-521445) (Fig. 10). Based on the RTPCR experiments completed thus far, HPnc2525 is at least 241bp and is located at
521426-521677 (Table 1 and Fig. 10).
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Figure 10. Walking Primer Strategy for HPnc2525
The green region corresponds to the putative sequence discovered previously by Ta et al.
(2012). The blue line corresponds to the experimentally discovered 5' end. The yellow
lines correspond to the sequence still yet to be experimentally verified. The gels shown
have controls for no reverse transcription and positive DNA. All samples are 5µl loaded
on 2% Agarose.
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Predicted Transcriptional Promoters and Terminators
A sequence, 'TATAAT', that exactly matched a known promoter sequence for
cagA was identified ~12nt from the TSS of HPnc2600111. There is no global consensus
for the -35 site in H. pylori. Virtual Footprint also identified 'TATAAT' as a Ϭ70 promoter
sequence, and no -35 sites were found. Based on this analysis, along with the BLAST and
MAFFT results, I predict the promoter consensus sequence among H. pylori strains to be
'TATAA(T/C)' for the -10 site for HPnc2600 (Fig. 11a). Virtual Footprint predicted the
promoter sequence 'CATAGT' for HPnc2525 located approximately 42bp upstream from
the sequence confirmed by the walking RT-PCR experiment and within the PHpcnc2525
promoter region. This result was a close match to the known promoter 'TATAGT' (Fig.
11b)114. For HPnc2645, I predict that the promoter sequence is 'CAATAC', which is
located approximately 86bp upstream from the 5'end sequence identified with the use
SMARter 3'/5'RACE experiment and within the PHPnc2645 promoter region. This result
was not close to a known promoter sequence, nor was this predicted by Virtual Footprint.
However, by visual identification, a highly conserved 5nt sequence was found during the
inspection of aligned sequences of PHpcnc2645 (Fig. 11c).
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Figure 11. Promoters Found for HPnc2525, HPnc2600, and HPnc2645
(A) Conserved promoter sequence of HPnc2600. The -10 sequence TATAA(C/T).
Prediction with Virtual Footprint – sigma70 – conservation shown with aligned microbe
Blast+Mafft. The orange highlight is the -50 upstream from HPnc2600 identified by
Sharma et al. (2010) with the -10 highlighted in grey. (B) Conserved promoter sequence
of HPnc2525 -10 'CATAGT' prediction with Virtual Footprint – sigma70 – conservation
shown with aligned microbe Blast+Mafft.HPnc2525. The orange highlight is upstream
from the experimentally identified region of HPnc2525 with the -10 located in the
functionally identified promoter region of PHPnc2525 in pink. (C) Conserved promoter
sequence of HPnc2645 -10 'CAATAC' prediction with– sigma70 – conservation shown
with aligned microbe Blast+Mafft. The orange highlight is upstream from the
experimentally identified region of HPnc2645 with the -10 located in the functionally
identified promoter region of PHPnc2645.
For HPnc2525, a putative RUT site was identified by RhoTermPredict
approximately 38bp downstream from the experimentally identified sequence (Table 4
and Fig. 12a&d).
Table 4. Predicted Putative RUT Site as Predicted by RhoTermPredict for HPnc2525.
mG27 Genomic
sRNA
Genomic sequence of putative RUT site
Position
HPnc2525 TTTTTACTTTTTTCTTTATCGTCATCTTTT
521705-521782
TTATTGCCACCTAAAGCCTTAGCTAATTT
AGCTTCTAAATTCTTATCC
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For both HPnc2600 and HPnc2645, a sequence 100nt upstream from sRNA 3'end
was analyzed with RNAfold for structure and energy, which ΔG any of the stems had to
have a ΔG < −3.0 kcal/mol (Fig. 12b,c,e,f)126,131.

Figure 12. Terminators Found for HPnc2525, HPnc2600, and HPnc2645
(A)Putative RUT site of HPnc2525 predicted by RhoTermPredict.
Predicted terminator (red) with respect to the experimentally identified sequence of
Hpnc2525. (B) Predicted terminator (red) location for HPnc2645 with respect to
HPnc2645 (partially cloned by Castillo & Baber, unpublished). (C) Predicted terminator
(red) location with respect to HPnc2600, discovered by Sharma et al. (2010). (D) Stemloop predicted by RhoTermPredict. (E) Stem-loop of HPnc2645 terminator, 14bp with a
loop <20% of stem length, -11.20 kcal/mol and upstream from HPnc2645. (F) Stem-loop
of HPnc2600 terminator, 19bp with a loop <20% of stem length, -5.71 kcal/mol and 2nt
upstream from HPnc2600.
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Identification of mRNA regulated by HPnc2525 and HPnc2600, and HPnc2645
The top 5 gene targets predicted by TargetRNA2 for HPnc2525, HPnc2600, and
HPnc2645 are reported in Tables 5, 6, 7, and 8, except hopZ due to its interest in
virulence being an outer membrane protein. Targets were predicted with TargetRNA2 in
both H. pylori strain 26695 and G27. Sharma et al. (2010) discovered HPnc2600 in H.
pylori strain 26695, and I am studying H. pylori strain G27. There was no identical
conserved target, but they had similar targets being within cagPAI. In H. pylori strain
26695, cagU is a known translocator protein or pilus protein and part of the T4SS found
in cagPAI132,133. In H. pylori G27, cagL, is also a translocator protein and which
translocates cagA into host cells134.
Table 5. Targets Predicted by Analysis of Experimentally Identified HPnc2525 Gene
Sequence in TargetRNA2
I included targets that fell below the TargetRNA2 recommended p-value < 0.010. Gene
fliA was included due to the potential relation to virulence.
Rank

Gene

Synonym

Energy

P-value

1

engA

HPG27_793

-16.01

0.000

2

-

HPG27_647

-15.85

0.000

3

-

HPG27_1140

-14.97

0.001

4

-

HPG27_825

-14.77

0.001

14

fliA

HPG27_396

-12.76

0.004

Function
GTP-binding protein EngA
succinyl-CoA-transferase
subunit A
30S ribosomal protein S7
CDP-diacylglycerol
pyrophosphatase
8-amino-7-oxononanoate
synthase
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Table 6. Targets Predicted by Analysis of sRNA HPnc2600 in H. pylori 26695 Gene
Sequence in TargetRNA2
TargetRNA2 recommends using p-value < 0.010.
Rank
Gene
Synonym Energy P-value
Function
1
hemC
HP0237
-19.17
0.000
Porpgobilinogen Deaminase
2
cagU
HP0531
-14.97
0.001
cagPAI protein cagU
3
Rnc
HP0662
-13.75
0.001
Ribonuclease III
Dimethyladenosine
4
ksgA
HP1431
-13.74
0.001
transferase
UDP-N-acetylglucosamine
5
HP1375
HP1375
-13.69
0.001
acyltransferase
Table 7. Targets Predicted by Analysis of sRNA Hpc2600 in H. pylori G27 Gene
Sequence in TargetRNA2
TargetRNA2 recommends using p-value < 0.010. Gene hopZ was included due to the
potential relation to virulence.
Rank

Gene

Synonym

Energy

P-value

1

folE

HPG27_877

-16.44

0.000

2

HPG27_1320

HPG27_1320

-15.75

0.000

3

HPG27_571

HPG27_571

-15.26

0.000

5

cagL

HPG27_497

-13.7

0.002
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hopZ

HPG27_8

-11.09

0.013

Function
GTP
cyclohydrolase I
UDP-Nacetylglucosami
ne
acyltransferase
ABC transporter
permease
cagPAI protein
cagL
Outer membrane
protein

Table 8. Targets Predicted by Analysis of Partial HPnc2645 Gene Sequence in
TargetRNA2
TargetRNA2 recommends using p-value < 0.010.
Rank Gene
Synonym
Energy P-value Function
1
rpsM HPG27_1246
-17.33
0.000
30S ribosomal protein S13
quinone-reactive Ni/Fe
2
hydB
HPG27_593
-13.85
0.002
hydrogenase
3
HPG27_139
-13.23
0.003
hypothetical protein
4
rpsJ
HPG27_1269
-12.95
0.004
30S ribosomal protein S10
tryptophanyl-tRNA
5
HPG27_1198
-12.68
0.005
synthetase
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Table 9. HPnc2600 Sequence Found by Sharma et al. (2010) in Helicobacter pylori
Strain 26695, and HPnc2600 in H. pylori Strain G27.
H. pylori G27 BLAST: 100% coverage, 93.3% identity, E-value=4e-149 (1e-50 is
considered very high quality)
sRNA
HPnc2600
(26695)

HPnc2600
(G27)

Sequence (5' end)
AGCAAATTTAAAAGATCATTGCTCTGTG
AGTTGCTAGGTGGTGGAGCGTTTAGCGG
ATTAGGTCCATGATGCTCTGTTGTATCGT
TCATGAAGCTCCTTTCAAGAATTAAATTG
AGAAATTGTTTTGTTATTATACCATTCTC
TCTCTGAGTTGTGATTGTCTTATCTCTTT
AAATTAGGCGCTTCTAAAATTTCATTACT
GGGTTACGACTGCTTACTCACTGCTCTTA
CTTTTTGAGTTGCATCGTATTTCATCTTG
CTTCTTGTTTGAAGCAATCCGCTACTTAC
ATTTATTATAGAGAATCTTTGCTCAACAC
CTTATCCAAAAAGATTCTTATTATAAGGT
AGCAAATTTAAAAGATCATTGCTCTGTG
AGTTGCTAGGTGGTGGGGCGTTTAGCGA
ATTGGATCCATGATGCTCTGTTGTATCGT
TCATGAAATTCCTTTCAAGAATTAAATTG
AGAAATTGTTTTGATATTATACCATTCTC
TCTCTGAGTTGTGATTGTCTTATCTCTTT
GAATTAGGCGCTTCTAAAATTTCATTACT
GATTACGACTGCTTACTTATTGCTCTTAC
TTTTTGAGTTGCATCGTGTTTCATCTTGC
TTCTTGTTTGAAGCAATCCGCTACCTTAC
ATTTATTATAAGGAATCTTTGTTCAACGC
CTTATCCAAAAAGGTTTTTATTAAAGGT

Genomic Position
564469-564124
(antisense to cagV)

530634-530978
(antisense to cagV)
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Further Directions
Functional Assay to Verify Predicted mRNA Targets
To evaluate TargetRNA2 predicted targets for their regulation by HPnc2525 and
HPnc2645, A Green-Fluorescent-Protein (GFP) plasmid-based gene expression reporter
system would be constructed. This reporter requires co-expression of (HPnc2525,
HPnc2600, or HPnc2645) and the predicted target, fused to GFP, from two different
plasmids in E. coli. If the sRNA regulates expression of the predicted target, it is
expected to see a change in fluorescence compared to control strains that do not express
the sRNA (Fig. 13).

Figure 13. Plasmid Expression Reporter
Expected fluorescence intensity result of E. coli cells transformed with psRNA-random
and pTARG compared to psRNA-cag and pTARG.
Plasmid psRNA would be constructed using an inverse PCR and Gibson assembly using
pJV300 provided by Dr. Jörg Vogel from the University of Würzburg. The selectable
marker for the constructed plasmids would be chloramphenicol.
Plasmid pTARG would be created for each predicted target that will include the
target promoter and open reading frame cloned in-frame with GFP, which will be
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accomplished by double digesting PxG10sf with NheiIHF and NsiIHF following the
manufacturer's instructions to make the backbone vector.
Plasmid PxG10 was also obtained from Dr. Jörg Vogel from the University of
Würzburg. The TargetRNA2 predicted sequences would be amplified via PCR from the
H. pylori G27 genome from purified DNA. This amplification of the promoter regions
and open reading frame will use oligonucleotides that will be ordered when the final
TargetRNA2 targets are predicted from the completely experimentally identified sRNA
sequences. These oligonucleotides will be designed to be ligated into the digested regions
of PxG10sf. The target PCR product will then be ligated into the digest. The selectable
marker for the constructed plasmids will be ampicillin.
The control plasmid used for this study is pJV300. Plasmid pJV300 is a built from
pZE12luc and contains a random sRNA sequence (Fig. 14).

Figure 14. Plasmids pTARG and psRNA
Each sRNA would be cloned downstream of the constitutive promoter in plasmid psRNA
to generate pHPnc2525, pHPnc2600, and pHPnc2645. The HPnc2525/2600/2645 genes
must be moved from the cloning vector to a plasmid that is specific for this expression
analysis. Each predicted sRNA target gene will be cloned downstream of a constitutive
promoter and upstream and in-frame with GFP in pTARG.
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Competent E. coli preparation and transformation
The cloned plasmids pHPnc2525, pHPnc2600, pHPnc2645, and pTARG would
be sequentially transformed into Escherichia coli (strain DH5α) via electroporation. For
the first transformation, competent E. coli will be prepared using a standard protocol
available in the lab. In brief, cells are cultured in Luria-Bertani (LB, 500mL) media to an
optical density (λ600) of approximately 0.5, then alternately centrifuged to pellet and
washed, 2X with ice-cold water and 1X with 10% glycerol. After the final centrifugation,
the cells are resuspended in 0.5mL ice-cold water, aliquoted to 50µl and stored at -80oC.
For the second transformation, competent E. coli containing the first plasmid will be
cultured in LB with an antibiotic (ampicillin 100µg/mL) to maintain that plasmid but
otherwise prepared in the same way. For the electroporations, 50µl electrocompetent E.
coli is mixed with 0.5 µl of the transforming DNA in a 2mm electroporation cuvette and
electroporated using standard E. coli settings on a BioRad electroporator. Transformed E.
coli would be cultured on LB media to select for transformation with the appropriate
plasmid, ampicillin (100µg/mL) for, and for chloramphenicol (100µg/mL) (Fig. 15)96.

Figure 15. Sequential Transformation of E. coli with sRNA Containing Plasmid
(psRNA-cag) and Target Gene Containing Plasmid (pTARG).
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Quantitation of target-GFP expression
Fluorescence due to target-GFP expression will be quantitated using TECAN
SpecTRFlourPlus Analysis. E. coli cultured in LB media plus selective antibiotics
(ampicillin and chloramphenicol) for approximately 12 hours would be transferred to a
96 well plate and scanned by excitation at 488nm wavelength and emittance at 510nm
wavelength. Fluorescence of E. coli would be compared with each psRNA and pTARG
combination to a control, psRNA random, and pTARG. A minimum of three independent
experiments with a minimum of 10 replicates each for each psRNA, and pTARG
combination would be conducted. The mean fluorescence value of E. coli with each
psRNA + pTARG would be compared to E. coli with psRNA-random+ pTARG (e.g.,
engA) using a two-tailed T-test.
Current Preparation for Further Study
Plasmid preparation
Plasmid pXG10sf was generously provided J. Vogel at the University of
Wurzburg, Germany. Due to the low copy number of pXG10sf, a more massive scale
plasmid prep was conducted (Qiagen Midiprep, Qiagen). This prep yielded 997.6ng/μl.
All other plasmids were prepared using small scale preparations, per the Qiagen miniprep
protocol (Qiagen). These preps yielded approximately10 to 20ng/ul.
DNA representing the mRNA targets
fliA was amplified from 0.5 µl genomic DNA with oligonucleotides fliA-F and
fliA-R, which add NheI-HF and NseI-HF restrictions sites and direct their in-frame
cloning with the GFP in pXG10sf (Appendix). Digestion of mRNA target amplicons was
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conducted using NheI-HF and NseI-HF (New England Biolabs) for 3 hours at 37oC with
no heat inactivation. The sample was cleanup via DNA precipitation (Appendix).
Table 10. Oligonucleotides used for further study.
fliA-F
GTTTTTATGCATGTCTATTTTTATCGCTTGCACGGAT
fliA-R
GTTTTGCTAGCCTTGGCTTAAAATATCAGCCATGATC
Assembly of the pXG10s vector and Target amplicons
Cloning of fliA was performed using OneTaq from NEB., however not yet
assembled.
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Discussion
Due to the global pandemic of COVID-19, some benchwork was not able to be
completed, and the experiments not able to be completed are mentioned in detail in the
"Further Directions" section. Because of this, the 3' and 5' ends of HPnc2525 and
HPnc2645 were not able to be finalized, thus preventing definitive structural analysis and
target verification. Target verification for HPnc2600 was also incomplete.
The promoters and terminators of HPnc2525, HPnc2600, and HPnc2645 were
searched for either computationally, visually, or consensus among multiple strains. These
were not able to be definitively verified experimentally due to lab closures. Direct
manipulation of HPnc2525, HPnc2600, and HPnc2645 will be needed to verify if these
are the correct promoters and terminators in H. pylori G27.
There is no known -35 consensus in the promoter search, which is due to H.
pylori not having a clear -35 consensus even with the same -10 sequence. The -35
sequence could also be experimentally discovered in future studies.
Although HPnc2600 is nearly identical between H. pylori strains 26695 and G27,
their predicted targets are different. The interesting targets being cagU for strain 26695
and cagL in strain G27. A blast between strains for cagU shows an e-value of 0.00 and
97.67% identity and cagL shoes an e-value of 0.00 and 96.5% identity. It would be
interesting to see if those targets hold true per strain. HPnc2600 may regulate cagU in
26695 but not cagL with the reverse in G27. It would be intriguing to see what is
regulating the non-targeted cag gene in the respective strains. Another possibility is that
the non-targeted cag gene may lack regulation in that strain. Further study would be
needed.

47

It is also unknown whether H. pylori uses a protein chaperone like Hfq in order to
protect the sRNA molecules. Searching for proteins with similar structural similarities to
Hfq in H. pylori could be undertaken in order to find a homologue to Hfq. Another
method could be to search evolutionarily. A BLAST search I completed yielded that
many bacterial species have Hfq genes. Some classes included in Proteobacteria,
excluding Gammaproteobacteria, have partial or similar genes to that of Hfq. Among the
Epsilonproteobacteria, which H. pylori is a member of, Campylobacter jejuni and
Arcobacter sp. both have partial Hfq sequences. However, from initial research the
sRNAs in found Epsilonproteobacteria may not conform to the same rules as they do in
Gammaproteobacteria135. It would be interesting to track the evolutionary changes to
these genes and sRNAs to see what, if any, genes play a role in chaperoning sRNA
molecules or how sRNA structural changes may negate the need for Hfq-like chaperones.
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APPENDIX
Table 11. Relevant Interleukins and Their Functions in the Human Immune System
Mentioned in this Paper.
Name

Target cells

Function

IL-1

T helper cells
B cells
NK cells
Macrophages,
Endothelium,
other
Neutrophils,
Basophils,
Lymphocytes
Macrophages
B cells
Mast cells
Th1 cells

Co-stimulation
Maturation & Proliferation
Activation
Inflammation
Tiny amounts induce acute phase reaction
Substantial amounts induce fever
Neutrophil chemotaxis

IL-8

IL-10

IL-12

Th2 cells
Activated T cells
NK cells

Cytokine production
Activation
Inhibits Th1 cytokine production (IFN-γ, TNF-β, IL2)
Stimulation
Differentiation into Cytotoxic T cells with IL2, ↑ IFN-γ, TNF-α, ↓ IL-10
↑ IFN-γ, TNF-α

Table 12. Blood Groups and Disease Risks136
Disease

Risk Factor

Blood Group/Antigens

Sickle cell anemia
Hemolytic disease of the
newborn
Chronic and autoimmune
hemolytic anemias
Vascular disorders, venous
and arterial
thromboembolism, coronary
heart disease, ischemic
stroke, myocardial infarction
Dementia, cognitive
impairment
Plague, cholera, tuberculosis,
mumps
Smallpox, Pseudomonas
aeruginosa
Gonorrhea, tuberculosis, S.
pneumoniae, E. coli,
salmonella

Increased adhesion
Antibodies to RhD

Adhesion Molecules
RhD

Rh null

Rh, RhAG

Reduced clearance of von
Willebrand factor and FVIII

Groups A > AB > B

Coagulation factors

Groups AB > B > A

Antigen profile

Group O

Antigen profile

Group A

Antigen profile

Group B
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Smallpox, E. coli, salmonella
N. meningitides, H.
influenza, C. albicans, S.
pneumoniae, E. coli urinary
tract infections, S. pyogenes,
V. cholera
H. pylori
Peptic ulcers, gastroduodenal
disease
Norovirus
P. falciparum malaria

Antigen profile
Antigen profile

Group AB
Non-secretors

Strain-dependent
Secretor status, H. pylori
strain
Strain-dependent
Receptor/antigen profile

P. vivax malaria
Cholera

Antigen profile
Severity differs by antigen
profile

Group A; 95% non-O
All non-secretors;
Group O
Secretors; groups O, A
Knops antigens; groups
A, B
Duffy FY antigens
Lewis antigen; nonsecretors; non-O
groups
Non-secretors; A, AB,
O blood groups

Bacterial Meningitis (N.
Antigen profile
meningitidis, H. influenza, S.
pneumoniae)
Cancer (tissue specific)
Increased tumor antigens
and ligands
Leukemia and Lymphoma
Non-Hodgkin’s central
nervous system lymphoma
(primary and secondary)
Hodgkin’s lymphoma
Acute lymphoblastic
leukemia
Acute myeloid leukemia
Stomach Cancer
Pancreatic Cancer
Von Hippel-Lindau and
Neuroendocrine
Multiple Endocrine
Neoplasia Type 1
Colon/Rectum Cancer

RBC membrane changes

A, B, H antigens lost;
“A- like” antigens
gained
A, B, H antigens lost
Group O, B

Group B
Group O

H. pylori strain
H. pylori strain
Multiple tumors

Group A
Group A
Group B > AB > A
Group O

Strongly associated

Group O

Hypertension
Hyperlipidemia

Type 1 and 2 chains; Lewis
antigens
3 phenotypes differ
Low fat diet Ineffective;
Intestinal ALP and apoB-48
vary by secretor status

Type 2 Diabetes
Type 1 Diabetes

Rh group modifies
FUT2 gene locus

Secretors; “A-like”
antigens expressed
Group B>A>AB
LDL: Heterozygous
MN; Group A, B;
ALP/apoB-48: Group
O and B secretors
Group AB > B > A
Non-secretors
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Table 13. cagPAI Gene Names104
26695 ORF Gene Number

Gene Name

HP0520

cag1

cagC

HP0521

cag2/Hypothetical

Hypothetical

HP0522

cag3

cagA

HP0523

cag4

cagγ

HP0524

cag5

cagβ

HP0525

-

cagα

HP0526

cag6

cagZ

HP0527

cag7

cagY

HP0528

cag8

cagX

HP0529

cag9

cagV

HP0530

cag10

cagW

HP0531

cag11

cagU

HP0532

cag12

cagT

HP0533

Hypothetical

Hypothetical

HP0534

cag13

cagS

HP0535

cag14

cagQ

HP0536

cag15

cagP

HP0537

cag16

cagM

HP0538

cag17

cagN

HP0539

cag18

cagL

HP0540

cag19

cagI
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HP0541

cag20

cagH

HP0542

cag21

cagG

HP0543

cag22

cagF

HP0544

cag23

cagE

HP0545

cag24

cagD

HP0546

cag15

cagC

HP0547

cag26

cagA

Table 14. SuperScript IV RT-PCR Temps
ID

Sequence

Tm

Ta

PIX-F

CACTCTTGCCTATAAAGGCC

57.4

61.2

PIX-R new

TATCAGTGAAATCGCTCTTAAGAACA

59.8

PIX-F

CACTCTTGCCTATAAAGGCC

57.4

PIX-R

GAAACTGCTAAGAATATCAGTG

53.8

PIX-F

CACTCTTGCCTATAAAGGCC

57.4

PIX-R2

AGATGTCGCAGAAACTGCTA

58.5

PIX-F

CACTCTTGCCTATAAAGGCC

57.4

PIX-R4

GAAAGCAATAAGATAGACAA

49.7

PIX-F

CACTCTTGCCTATAAAGGCC

57.4

PIX-R9

GTGGCAATAAAAAAGATGACGATAAG

58.5

PIX-R new

TATCAGTGAAATCGCTCTTAAGAACA

59.8

PIX-F2

AATGTGGGATCACTCTTGCC

56.9

PIX-R new

TATCAGTGAAATCGCTCTTAAGAACA

59.8

57.8

61.2
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61.2

63.3

61.9

60

ID

Sequence

Tm

PIX-F4

GGGTGTATTGCGCTAAAACA

58.1

PIX-R new

TATCAGTGAAATCGCTCTTAAGAACA

59.8

PIX-F8

TATACCTGTGCTACTTTAGA

51.6

Ta

55.8

Blood Agar Plates for Helicobacter pylori growth (from Antonello Covarcci, 11/95)
1. Dissolve correct mass of Columbia Agar in dH20 to 1 liter.
2. Autoclave on liquid cycle
3. WHILE AUTOCLAVING: Mix fresh ß Cyclodextrin.
4. Add ß-Cyclodextrin at 1 mL per 100 mL agar
5. ß-Cyclodextrin should be 200 mg/ml in DMSO
6. Cool media to about 55˚C
7. Mix blood and add 5 ml blood per 100 ml agar.
8. Add ß-Cyclodextrin 1 mL per 100 mL agar
9. Swirl gently and pour
LB Plates (Chloramphenicol and Ampicillin)
1. Dissolve correct mass of Luria Bertani broth (check container) in dH20 to 1 liter.
2. Add 25g LB powder to a flask
3. Mix to resuspend powder
4. Autoclave
5. Add either 20µg/ml Chloramphenicol or 100µg/ml Ampicillin
6. Gently pour plates
2% Agarose Gel
1. 50ml 1% TAE Buffer
2. 1g Agarose
3. Microwave for ~2min
4. Pour gel with a comb
5. Sit at room temperature for 15min
6. Cover gel with 1% TAE in the tray and run sample
7. When complete place gel in a tray covered with dH2O
8. Add 8µ EtBr to tray dH20
9. Place tray on a rocker for 15min
10. Image with UV light
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